Results

1–10 of 32 results for Anti VEGF

Efficacy, Safety, and Durability of Faricimab in Macular Edema Due to Retinal Vein Occlusion:72-Week Results From the Phase 3 BALATON and COMINO Trials
Carl J Danzig, MD
Updates from the Field
2024
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024
Endophthalmitis After Intravitreal Injections with 0.05% Aqueous Chlorhexidine vs 5% Povidone-Iodine as Ocular Antiseptics
Murtaza K Adam, MD
Annual Meeting Talks
2022
Impact of COVID-19 and Delay on Macular Edema After Retinal Vein Occlusion (MEfRVO) Comparing Ozurdex vs Anti-VEGF Therapy
John J. Huang, MD
Annual Meeting Talks
2022
ADVM-022 Intravitreal Gene Therapy for Neovascular AMD: Phase 1 OPTIC Trial Update
Dante Joseph Pieramici, MD
Annual Meeting Talks
2022
Debate: Should We Use Anti-VEGF in Pregnancy?
Dimitra Skondra, MD,PhD
Updates from the Field
2024
Survey of Intravitreal Injection Technique Among Retina Specialists in Mexico
Gabriela Lopezcarasa Hernandez, MD
On Demand Cases, Courses, and Papers
2021
Quality Assessment of a New Silicone-Free Syringe Developed for Intravitreal Injections
Gustavo Barreto de Melo, MD, PhD, FASRS
On Demand Cases, Courses, and Papers
2021
PRN Cycles of Three Monthly Anti-VEGF Injections in Diabetic Macular Edema: 12- and 24-Month Results
Ahmad Rehmani, DO
On Demand Cases, Courses, and Papers
2021
Impact of Duration of Exposure to Residual Intraretinal Fluid on Visual Function Outcomes in Neovascular Age-Related Macular Degeneration (nAMD)
Nathan C. Steinle, MD
On Demand Cases, Courses, and Papers
2021